Infection and Risk of Parkinson's Disease
- PMID: 33361610
- PMCID: PMC7990414
- DOI: 10.3233/JPD-202279
Infection and Risk of Parkinson's Disease
Abstract
Parkinson's disease (PD) is thought to be caused by a combination of genetic and environmental factors. Bacterial or viral infection has been proposed as a potential risk factor, and there is supporting although not entirely consistent epidemiologic and basic science evidence to support its role. Encephalitis caused by influenza has included parkinsonian features. Epidemiological evidence is most compelling for an association between PD and hepatitis C virus. Infection with Helicobacter pylori may be associated not only with PD risk but also response to levodopa. Rapidly evolving knowledge regarding the role of the microbiome also suggests a role of resident bacteria in PD risk. Biological plausibility for the role for infectious agents is supported by the known neurotropic effects of specific viruses, particular vulnerability of the substantia nigra and even the promotion of aggregation of alpha-synuclein. A common feature of implicated viruses appears to be production of high levels of cytokines and chemokines that can cross the blood-brain barrier leading to microglial activation and inflammation and ultimately neuronal cell death. Based on multiple avenues of evidence it appears likely that specific bacterial and particularly viral infections may increase vulnerability to PD. The implications of this for PD prevention requires attention and may be most relevant once preventive treatments for at-risk populations are developed.
Keywords: Parkinson’s disease; bacteria; etiology; infection; viruses.
Conflict of interest statement
The authors have no conflicts of interest to declare.
Dr. Smeyne receives research support from the National Institute of Neurological Disorders and Str-oke and the National Institute of Environmental Health Science.
Dr. Marras Receives research support from the Parkinson’s Foundation (US), Michael J Fox Foundation, Canadian Institutes of Health Research and is a site investigator for a clinical trial supported by Theravance.
Dr. Savica receives research support from the National Institute on Aging, the National Institute of Neurological Disorders and Stroke, and the Mayo Clinic Small Grants Program National Center for Advancing Translational Sciences (NCATS) and Acadia Pharmaceuticals Inc.
Dr. Noyce is funded by the Barts Charity. He reports additional grants from Parkinson’s UK, Ali-gning Science Across Parkinson’s (ASAP) and Michael J Fox Foundation (MJFF), the Virginia Kieley Benefaction, grants and non-financial support from GE Healthcare, and personal fees from Bial, Britannia, AbbVie, Profile, F. Hoffmann-La Roche and Biogen.
Figures
References
-
- Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, Tan M, Kia DA, Noyce AJ, Xue A, Bras J, Young E, von Coelln R, Simón-Sánchez J, Schulte C, Sharma M, Krohn L, Pihlstrøm L, Siitonen A, Iwaki H, Leonard H, Faghri F, Gibbs JR, Hernandez DG, Scholz SW, Botia JA, Martinez M, Corvol JC, Lesage S, Jankovic J, Shulman LM, Sutherland M, Tienari P, Majamaa K, Toft M, Andreassen OA, Bangale T, Brice A, Yang J, Gan-Or Z, Gasser T, Heutink P, Shulman JM, Wood NW, Hinds DA, Hardy JA, Morris HR, Gratten J, Visscher PM, Graham RR, Singleton AB (2019) Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: A meta-analysis of genome-wide association studies. Lancet Neurol 18, 1091–1102. - PMC - PubMed
-
- Marras C, Canning CG, Goldman SM (2019) Environment, lifestyle, and Parkinson’s disease: Implications for prevention in the next decade. Mov Disord 34, 801–811. - PubMed
-
- Casals J, Elizan TS, Yahr MD (1998) Postencephalitic parkinsonism–a review. J Neural Transm (Vienna) 105, 645–676. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
